Opeyemi Jegede

18PUBLICATIONS
159CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.

|Feb 09, 2026
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Catherine Diefenbach, Opeyemi Jegede, Victoria Wang

|Jul 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.

Charlene M Mantia, Opeyemi A Jegede, David F McDermott

|Feb 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.

Miya B Hugaboom, Lena V Wirth, Kelly Street

|Dec 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.

Marjorie G Zauderer, Opeyemi Jegede, David M Jackman

|Oct 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.

Mark H O'Hara, Opeyemi Jegede, Mark A Dickson

Pageof 3

Frequent Collaborators

7 joint publications

Michael B Atkins

6 joint publications

Sabina Signoretti

5 joint publications

David F McDermott

4 joint publications

David Braun